| Q39166725 | A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. |
| Q59353641 | Absence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients |
| Q35114397 | Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia |
| Q92519107 | Acute Myeloid Leukemia Mutations: Therapeutic Implications |
| Q36849666 | Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification |
| Q38027047 | Acute myeloid leukemia with normal cytogenetics |
| Q34598109 | Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia |
| Q27851713 | Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia |
| Q26996818 | Allogeneic stem cell transplantation in first complete remission |
| Q26797245 | Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis |
| Q34340438 | Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations |
| Q37363129 | Clinical implications of molecular genetic aberrations in acute myeloid leukemia |
| Q33758306 | Comprehensive mutational profiling of core binding factor acute myeloid leukemia |
| Q37089717 | Cooperating gene mutations in acute myeloid leukemia: a review of the literature. |
| Q97884624 | Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review) |
| Q81822020 | Current status of blood and marrow transplantation for patients with AML |
| Q49481329 | Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population |
| Q39674948 | Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis |
| Q33776896 | E-26 Transformation-specific Related Gene Expression and Outcomes in Cytogenetically Normal Acute Myeloid Leukemia: A Meta-analysis |
| Q64250050 | Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia |
| Q27851415 | FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications |
| Q84615573 | FLT3 Mutations at Diagnosis and Relapse in Acute Myeloid Leukemia: Cytogenetic and Pathologic Correlations, Including Cuplike Blast Morphology |
| Q38026453 | FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia |
| Q35048217 | FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? |
| Q27028163 | FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? |
| Q39282600 | FLT3-ITD and its current role in acute myeloid leukaemia |
| Q37421401 | FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice |
| Q37631580 | Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients |
| Q33555627 | Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia |
| Q34154213 | High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia |
| Q37623389 | How I treat FLT3-mutated AML. |
| Q53245841 | Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. |
| Q21285040 | JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms |
| Q38712298 | Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation |
| Q37809866 | Molecular diagnosis of acute myeloid leukemia |
| Q26776393 | Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance |
| Q38026007 | Molecular markers in acute myeloid leukaemia |
| Q37815040 | Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives |
| Q26998811 | Molecular prognostic factors in cytogenetically normal acute myeloid leukemia |
| Q92061916 | Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia |
| Q43014298 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following All |
| Q37412298 | New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia |
| Q36356082 | Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia |
| Q59793137 | Novel Agents for Acute Myeloid Leukemia |
| Q39656943 | Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors |
| Q58054015 | Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia |
| Q42721533 | Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse |
| Q38196743 | Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia |
| Q33913329 | Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia |
| Q56345117 | Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML |
| Q34095013 | Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia |
| Q33986236 | Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia |
| Q37347511 | Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol |
| Q42785026 | Prognostic significance of the FLT3 ITD mutation in patients with normal-karyotype acute myeloid leukemia in relapse |
| Q34285937 | Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia |
| Q48285471 | Radiotherapy for extramedullary leukaemic manifestation (Chloroma). |
| Q40396505 | Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation |
| Q39893812 | Repression of Gadd45alpha by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation |
| Q64064165 | Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors |
| Q37842861 | Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution |
| Q98779175 | Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review |
| Q36469916 | Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns |
| Q24338964 | Structural and functional alterations of FLT3 in acute myeloid leukemia |
| Q34109454 | Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results |
| Q50629545 | TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. |
| Q58555667 | Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance |
| Q38011962 | Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia |
| Q34555386 | The Future of Targeting FLT3 Activation in AML. |
| Q50893694 | The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. |
| Q39302268 | The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia |
| Q40202671 | The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China |
| Q37738548 | The role of molecular tests in acute myelogenous leukemia treatment decisions |
| Q38235586 | Translational implications of somatic genomics in acute myeloid leukaemia. |
| Q39699250 | Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation |